A Phase 2 interventional study of IncobotulinumtoxinA and Placebo in Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury, sponsored by Merz Therapeutics GmbH. Completed at 31 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Merz Therapeutics GmbH (part of Merz Pharma) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Neuralgia, Postherpetic with a site in Poland — none open to participants now, none under way, none of them phase 3. Neuralgia, Postherpetic · Poland.
Among the 11 studies in Neuralgia, Postherpetic with a site in Poland, this one is the 10th largest by enrollment, is the only one that started in 2023, is one of 7 in phase 2, and was the 11th registered.
197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.
Browse Neuralgia, Postherpetic studies →None of the 11 studies in Neuralgia, Postherpetic with a site in Poland is open now. The open studies under Neuralgia, Postherpetic, anywhere →
Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 2 · Phase 4 2
First in 2004; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.
Median enrollment 280 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merz Therapeutics GmbH, one of the names counted as Merz Pharma. Under that name alone:
Merz Therapeutics GmbH is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Merz Pharma has 1 study filed under Neuralgia, Postherpetic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Neuralgia, Postherpetic with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this clinical trial, participants with nerve pain after shingles or nerve injury will receive injections with NT 201 or placebo. The purpose is to measure the decrease of nerve pain with NT 201 compared to placebo.
Trial details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subcutaneous injections of up to 300 units NT 201 into the peripheral neuropathic pain area
Biological: IncobotulinumtoxinA
Subcutaneous injections of placebo into the peripheral neuropathic pain area
Biological: Placebo
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
Also known as: Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, NT 201
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Weekly averages of changes from baseline in Average Daily Pain (ADP) intensity at Weeks 2 to 12.
Time frame: Baseline to week 2 to 12
Changes from baseline in Neuropathic Pain Symptom Inventory (NPSI) total score at Weeks 2 to 12
Time frame: Baseline to week 2 to 12
Incidence of treatment-emergent adverse events (TEAEs) related to study intervention as assessed by the investigator from intervention to end of study.
Time frame: Baseline to week 20
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in May 2025, 17 months.
Of 12 phase 2 interventional studies under Neuralgia, Postherpetic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 17 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A